ArticleSignal transduction and targeted therapy2021
SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern.
Article in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.International journal of biological sciences · 2022Pooled it
- A Bibliometric Analysis on Multi-epitope Vaccine Development Against SARS-CoV-2: Current Status, Development, and Future Directions.Molecular biotechnology · 2026Review
- Myocarditis After mRNA Vaccination: A Metabolic-Innate Immune Cascade Centered on Lipid Nanoparticles.Mediators of inflammation · 2026Review
- Convergent Evolution and Host-Limiting Impacts of SARS-CoV-2 Revealed by Cellular Experiments.Molecular biology and evolution · 2025Article
- CovidTGI: A tool to investigate the temporal genetic instability of SARS-CoV-2 variants.iScience · 2025Article
- Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine.European journal of microbiology & immunology · 2024Article
- The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2.The AAPS journal · 2024Review
- The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice.Vaccines · 2024Article
- Human coronavirus OC43-elicited CD4Nature communications · 2024Article
- FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Review
- Comparison of Two Commercially Available Interferon-γ Release Assays for T-Cell-Mediated Immunity and Evaluation of Humoral Immunity against SARS-CoV-2 in Healthcare Workers.Diagnostics (Basel, Switzerland) · 2023Article
- Infectious diseases genomic surveillance capacity in the Caribbean: A retrospective analysis of SARS-CoV-2.Lancet regional health. Americas · 2023Article
- Article
- Article
- Article
- Article
- CEBIT screening for inhibitors of the interaction between SARS-CoV-2 spike and ACE2.Fundamental research · 2022Article
- BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality.Nature microbiology · 2022Article
- Synthesis, crystal structure elucidation, DFT analysis, drug-likeness and ADMET evaluation and molecular docking studies of triazole derivatives: Binary inhibition of spike protein and ACE2 receptor protein of COVID-19.Journal of the Chinese Chemical Society. Zhongguo hua xue hui (Taipei, Taiwan) · 2022Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.